1. Bajwa EK, Ayas NT, Schulzer M, Mak E, Ryu JH, Malhotra A. Interferon-1b therapy in idiopathic pulmonary fibrosis: a mata-analysis. Chest. 2005. 128:203–206.
2. Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004. 350:125–133.
3. Antoniou KM, Nicholson AG, Dimadi M, Malagari K, Latsi P, Rapti A, et al. Long-term clinical effect of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Resp J. 2006. 28:496–504.
4. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005. 353:2229–2242.
5. Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Am J Respir Crit Care Med. 1997. 156:1897–1901.
6. Date H, Tanimoto Y, Goto K, Yamadori I, Aoe M, Sano Y, et al. A new treatment strategy for advanced idiopathic interstitial pneumonia: living-donor lobar lung transplantation. Chst. 2005. 128:1364–1370.
7. Jegal Y, Kim DS, Shim TS, Lim C, Lee SD, Koh Y, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005. 171:639–644.
8. Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005. 142:963–967.
9. Selman M, Pardo A, Barrera L, Estrada A, Watson SR, Wilson K, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med. 2006. 173:188–198.